Nykode Therapeutics As (VACBF) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nykode Therapeutics Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.378 Greetings, and welcome to the NICODE Therapeutics Q1 2026 Financial Results 00:00:05.378 -- 00:00:10.424 Presentation. At this time, all participants are in listening mode. 00:00:10.424 -- 00:00:14.369 A question and answer session will follow the formal presentation. 00:00:14.369 -- 00:00:18.574 You may ask a question at any time by typing it into the Ask a Question feature on your 00:00:18.574 -- 00:00:23.140 screen. As a reminder, this conference is being recorded. 00:00:23.140 -- 00:00:27.465 It's now my pleasure to turn the call over to NICODE CEO, Michael Engsig. 00:00:27.465 -- 00:00:30.018 Please go ahead, sir. 00:00:30.018 -- 00:00:34.064 Thank you very much, Kevin. And also from my side, a very warm welcome to all our listeners 00:00:34.064 -- 00:00:39.412 to this, our first quarter webcast on this beautiful summer day in Oslo. 00:00:39.412 -- 00:00:45.240 A quick look at our forward-looking statement, which I think you are all familiar. 00:00:45.240 -- 00:00:48.906 On that basis, we will move forward. 00:00:48.906 -- 00:00:51.427 As usual, it 00:00:51.850 -- 00:00:56.918 is a pleasure to have with me today, Anita Fredriksson, our co-founder, chief scientific 00:00:56.918 -- 00:01:02.088 officer, and head of business development As well as how our chief financial 00:01:02.088 -- 00:01:03.610 officer. 00:01:03.610 -- 00:01:07.995 Taking you through the highlights of of the quarter that the deep dive into some of the 00:01:07.995 -- 00:01:13.640 data and of course, the financial numbers also. 00:01:14.503 -- 00:01:19.749 So, for the new listeners, a very quick recap, my code is a chemical stage immunotherapy 00:01:19.749 -- 00:01:24.935 company. focus on leveraging our antigen-presenting cell targeted immunotherapy platform...